FLUCONAZOLE CYCLOSPORINE INTERACTION - A DOSE-DEPENDENT EFFECT

被引:53
作者
LOPEZGIL, JA
机构
[1] Resident in Clinical Pharmacology, Clinical Pharmacology Service, Hospital Universitario “Marqués de Valdecilla”, 39008, Santander
关键词
D O I
10.1177/106002809302700405
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To present cases supporting the hypothesis that fluconazole inhibition of cyclosporine metabolism is dose-dependent. DESIGN: Case reports. PATIENTS AND INTERVENTIONS: One renal-pancreatic transplant patient taking fluconazole 100 and 300 mg/d for 37 and 17 days, respectively; four bone marrow transplant recipients taking fluconazole 100 mg/d as antifungal prophylaxis and five other concurrent nonmatched recipients whose antifungal prophylactic agent is nystatin mouthwash. All of these patients underwent transplantation during the same period. RESULTS: There was a sharp rise in cyclosporine trough concentration (ng/mL), concentration:dose ratio (ng.mL-1/mg.kg-1), and serum creatinine concentration (mumol/L) in the renal-pancreatic transplantation patient taking fluconazole 300 mg/d. No such increase occurred at 100 mg/d. No significant alterations in cyclosporine concentration:dose ratio were seen in the patients undergoing bone marrow transplantation and receiving fluconazole 100 mg/d. CONCLUSIONS: The case of the renal-pancreatic transplantation patient shows a characteristic interaction profile, and it supports the hypothesis of a dose-dependent interaction between cyclosporine and fluconazole. Given the nephrotoxic potential of the immunosuppressant drug, dosage reduction and closer monitoring of cyclosporine concentrations and/or renal function in patients receiving fluconazole dosages greater than 200 mg/d must be considered.
引用
收藏
页码:427 / 430
页数:4
相关论文
共 21 条
[1]  
CANAFAX DM, 1991, TRANSPLANT P, V23, P1041
[2]   INTERACTION BETWEEN CYCLOSPORINE AND FLUCONAZOLE IN RENAL-ALLOGRAFT RECIPIENTS [J].
CANAFAX, DM ;
GRAVES, NM ;
HILLIGOSS, DM ;
CARLETON, BC ;
GARDNER, MJ ;
MATAS, AJ .
TRANSPLANTATION, 1991, 51 (05) :1014-1018
[3]  
CONTI DJ, 1989, TRANSPLANTATION, V48, P692
[4]  
EHNINGER G, 1989, LANCET, V2, P104
[5]   HEART-TRANSPLANTATION IN MILDLY DIABETIC-PATIENTS [J].
FAGLIA, E ;
FAVALES, F ;
MAZZOLA, E ;
PIZZI, G ;
DEMARIA, R ;
MANGIAVACCHI, M ;
GRONDA, E ;
CAROLI, A ;
ZAINA, MS .
DIABETES, 1990, 39 (06) :740-742
[6]   A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
GOODMAN, JL ;
WINSTON, DJ ;
GREENFIELD, RA ;
CHANDRASEKAR, PH ;
FOX, B ;
KAIZER, H ;
SHADDUCK, RK ;
SHEA, TC ;
STIFF, P ;
FRIEDMAN, DJ ;
POWDERLY, WG ;
SILBER, JL ;
HOROWITZ, H ;
LICHTIN, A ;
WOLFF, SN ;
MANGAN, KF ;
SILVER, SM ;
WEISDORF, D ;
HO, WG ;
GILBERT, G ;
BUELL, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) :845-851
[7]   CYCLOSPORIN-ERYTHROMYCIN INTERACTION IN RENAL-TRANSPLANT PATIENTS [J].
GUPTA, SK ;
BAKRAN, A ;
JOHNSON, RWG ;
ROWLAND, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (04) :475-481
[8]  
KAHAN BD, 1990, TRANSPLANT P, V22, P1274
[9]   DEMOGRAPHIC-FACTORS AFFECTING THE PHARMACOKINETICS OF CYCLOSPORINE ESTIMATED BY RADIOIMMUNOASSAY [J].
KAHAN, BD ;
KRAMER, WG ;
WIDEMAN, C ;
FLECHNER, SM ;
LORBER, MI ;
VANBUREN, CT .
TRANSPLANTATION, 1986, 41 (04) :459-464
[10]  
KRUGER HU, 1988, BONE MARROW TRANSPL, V3, P271